Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Combined bone marrow mesenchymal stem cell-derived nanovesicles and low-level laser therapy potentiate proliferation and osteogenesis of bone marrow mesenchymal stem cells

Zhang J., Yao T., Han Q., Mo Y., Li D., Zhang Z.

Laboratory Study, published in Front Bioeng Biotechnol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Front Bioeng Biotechnol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41446652
PMCID
PMC12723869
DOI
10.3389/fbioe.2025.1676777
Citations
1

Abstract (original English)

Background Addressing the persistent challenge of bone defect repair requires innovative bioengineering strategies. Enhancing the biological activity of bone marrow mesenchymal stem cells (BMSCs) is pivotal for effective bone regeneration. This study develops a novel combinatorial bioengineering approach leveraging two distinct biotechnological modalities: low-level laser therapy (LLLT) and bone marrow mesenchymal stem cell-derived nanovesicles (BMSC-NVs). LLLT, a non-invasive biophysical stimulation technique with defined light parameters, is known to prime cellular responses. Concurrently, BMSC-NVs represent an emerging engineered cell-free therapeutic platform with significant promise for tissue regeneration. Thus, we hypothesize that combining LLLT's direct regulatory effects on BMSCs with the bioactive cargo of BMSC-NVs will synergistically enhance BMSC function. This study presents the first evaluation of the combined impact of LLLT and BMSC-NVs on the proliferation and osteogenic differentiation of rat BMSCs in vitro . Methods Cell proliferation was quantified using CCK-8 assay, while osteogenic differentiation was assessed through alkaline phosphatase staining, alizarin red staining, and real-time quantitative polymerase chain reaction (osteogenic gene expression). Results The LLLT+BMSC-NVs combinatorial strategy effectively enhances BMSC proliferation capacity (as indi

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.